Biodefense Market Size & Forecast 2035
The global biodefense market was valued at USD 17.70 billion in 2025 and is forecast to reach USD 30.81 billion by 2035, advancing at a 5.7% compound annual growth rate during 2026-2035.
Biodefense covers vaccines, therapeutics, antitoxins, diagnostics, detection systems and supporting services designed to prevent, identify or treat exposure to biological agents. Government procurement remains the economic center of the market. Revenue is shaped by multiyear preparedness contracts, stockpile replenishment cycles, shelf-life extension decisions, manufacturing-readiness payments and emergency orders rather than routine prescription demand alone.
The market is entering a more diversified procurement phase. Established programs for anthrax, smallpox and botulism still account for most commercial revenue, but agencies are also funding platform technologies that can move from pathogen identification to candidate selection and scaled manufacturing faster. This shift favors suppliers with proven regulatory execution, validated manufacturing capacity and the ability to deliver under government contracting rules.
Market Dynamics
Procurement is moving from single-product stockpiling to portfolio readiness
Preparedness agencies are maintaining proven countermeasures while adding rapid-response capabilities. BARDA reported 713 award actions and USD 1.896 billion in obligations during fiscal 2025, alongside more than 200 active industry partnerships and a contract portfolio exceeding USD 120 billion. These figures show that biodefense competition is not limited to product efficacy. Contract execution, surge manufacturing, quality systems, supply assurance and delivery timing determine whether a technology becomes a durable procurement program.
The commercial effect is visible in recent awards. Emergent BioSolutions reported more than USD 450 million in 2025 medical-countermeasure awards, options and orders, including programs for botulism, smallpox and anthrax. In 2026, Bavarian Nordic reported multiple public-preparedness orders, while SIGA recorded deliveries of oral and intravenous TPOXX to domestic and international stockpiles. These transactions support a market structure in which a limited number of validated products can generate sizable but uneven revenue.
Platform validation is becoming a distinct buying category
In October 2026, BARDA selected nine priority emerging viruses to test whether rapid-response platforms can generate usable countermeasures across different viral families. The program changes the value proposition for developers. A supplier that demonstrates repeatable speed across several pathogens can compete for preparedness funding before a single threat becomes a large commercial indication.
This favors adaptable vaccine constructs, broad-spectrum antivirals, modular diagnostics and manufacturing systems that share processes across products. It also raises the evidence threshold: agencies require reproducible timelines, regulatory plans and manufacturing controls, not only promising laboratory results.
Domestic manufacturing capacity is becoming part of the product
BARDA states that it has invested more than USD 2 billion in the domestic medical-countermeasure manufacturing base. The investment reflects a procurement lesson from recent health emergencies: an approved countermeasure has limited strategic value if critical inputs, fill-finish capacity or validated production lines cannot scale during an incident.
Contract terms increasingly reward warm-base capacity, technology transfer readiness and supply-chain visibility. This can lift fixed operating costs for manufacturers, yet it also creates service revenue from readiness, process development, quality assurance and lifecycle management.
Regulatory pathways remain a barrier to new entrants
Human efficacy trials cannot be conducted ethically for several high-consequence threats. Developers may therefore need to use the FDA Animal Rule, validated correlates of protection and carefully designed safety studies. DynPort Vaccine Company reports that its teams have advanced six biodefense products into clinical development and one to licensure, illustrating the specialized regulatory and program-management work required.
The barrier is not scientific novelty alone. Developers must coordinate animal models, analytical assays, manufacturing comparability, stability data and government-furnished requirements. Smaller biotechnology companies often need an experienced development partner before their asset is ready for procurement.
Revenue concentration and contract timing create volatility
Biodefense orders are large, but their timing is difficult to smooth. A delayed option exercise, inspection, lot release or delivery can shift revenue between quarters. SIGA’s business updates show how a small number of oral and intravenous TPOXX deliveries can materially affect annual performance. Suppliers need working capital and manufacturing flexibility to manage the gap between award, production, acceptance and revenue recognition.
Market Segmentation
By threat: anthrax remains the largest revenue pool
Anthrax accounted for an estimated 29.4% of 2025 revenue, equal to USD 5.20 billion. The segment is supported by layered preparedness: prophylactic vaccines, post-exposure vaccines, immune globulin, monoclonal antibodies, antibiotics and diagnostic capabilities. Emergent’s portfolio includes BioThrax, CYFENDUS, ANTHRASIL and raxibacumab, which demonstrates the breadth of products attached to one threat category.
Smallpox and mpox represented 24.8%, or USD 4.39 billion. Revenue includes vaccines, antivirals, immune globulin and stockpile services. Government orders for freeze-dried MVA-BN vaccine and deliveries of oral and intravenous TPOXX show that the category is moving beyond a single-market stockpile model. International procurement is broadening, but regulatory labeling, national threat assessments and budget timing still vary by country.
Radiological and nuclear medical countermeasures contributed 18.6%, or USD 3.29 billion. This segment includes treatments for radiation injury, contamination management, diagnostics and readiness services. Growth is linked to civil-defense planning and military preparedness, although product development remains technically demanding because clinical efficacy often relies on surrogate endpoints and nonhuman evidence.
Botulism represented 9.7%, or USD 1.72 billion. The category is narrower than anthrax or smallpox, but it benefits from high strategic importance and specialized antitoxin procurement. Emergent reported a USD 62.4 million BAT contract award in 2025, confirming that replacement and readiness orders can remain commercially significant within a smaller threat segment.
Other biological threats accounted for 17.5%, or USD 3.10 billion. This group includes viral hemorrhagic fevers, plague, tularemia, emerging viruses and broad-spectrum countermeasures. Its share is likely to rise as platform-based programs convert early development funding into validated candidates and procurement options.
By countermeasure: vaccines lead, while platform technologies reshape the mix
Vaccines generated an estimated 39.5% of 2025 revenue, equal to USD 6.99 billion. Anthrax and orthopoxvirus preparedness programs underpin the segment. Vaccine suppliers compete on immunogenicity, dosing schedules, storage profile, production yield, lot-release reliability and the ability to maintain surge capacity.
Therapeutics and antitoxins captured 28.6%, or USD 5.06 billion. The segment includes antivirals, monoclonal and polyclonal antibodies, immune globulins and toxin-specific treatments. TPOXX, BAT, ANTHRASIL, raxibacumab, TEMBEXA and EBANGA illustrate the category’s mix of pathogen-specific products. Its commercial profile is procurement-heavy, with revenue concentrated in government orders.
Diagnostics and detection systems held 18.1%, or USD 3.20 billion. Demand covers laboratory confirmation, field detection, surveillance and assay-development services. Faster identification has direct operational value because agencies must distinguish a deliberate release from a naturally occurring outbreak and select an effective countermeasure without avoidable delay.
Personal protection, decontamination and other preparedness products represented 13.8%, or USD 2.44 billion. The group includes protective systems, decontamination products, readiness services and program support. Growth is tied to integrated response planning rather than pharmaceutical procurement alone.
By end user: research organizations retain the leading share under the report taxonomy
Research organizations accounted for an estimated 42.7% of 2025 revenue, equal to USD 7.56 billion. The category includes government-supported laboratories, contract research networks, product-development partners and organizations managing nonclinical, clinical and analytical programs. Their leading position reflects the long development path between threat identification and stockpile procurement.
Hospitals and health systems represented 35.4%, or USD 6.27 billion. Spending includes diagnostics, treatment readiness, infection-control products and emergency preparedness capabilities. Hospital demand is influenced by public-health funding and incident-readiness requirements rather than ordinary bed occupancy.
Other end users held 21.9%, or USD 3.88 billion. This category covers military units, public-health agencies, emergency-response bodies and specialized government programs not captured under research organizations or hospitals. Although procurement authorities fund a substantial part of the total market, the end-user classification records where products and services are deployed or managed.
Regional and country analysis
North America
North America led the market with an estimated 52.8% share in 2025, equal to USD 9.35 billion. The United States alone represented 48.7% of global revenue, or USD 8.62 billion, while Canada contributed 3.1%, or USD 0.55 billion; the remaining North American revenue came from Mexico and regional programs.
The U.S. lead is supported by BARDA, the Strategic National Stockpile, Department of Defense programs and a domestic network spanning discovery, advanced development, manufacturing and procurement. The region’s current change is not a simple increase in spending. Agencies are testing whether platform technologies can deliver across multiple pathogens and are paying for domestic readiness alongside finished doses. This broadens the addressable market for contract development, regulatory support, assay validation and manufacturing infrastructure.
Canada’s market is smaller but strategically linked to cross-border health security, national stockpiles and established regulatory cooperation. Procurement opportunities concentrate in vaccines, diagnostics, emergency treatment and public-health readiness.
Europe
Europe held an estimated 22.9% share, equal to USD 4.05 billion in 2025. Germany represented 4.8% of the global market, or USD 0.85 billion; the United Kingdom held 4.3%, or USD 0.76 billion; and France accounted for 3.7%, or USD 0.65 billion. The rest of Europe contributed USD 1.79 billion.
European demand is moving toward coordinated preparedness and supply security, but national purchasing remains important. Bavarian Nordic’s June 2026 contract valued at more than DKK 700 million covered smallpox and mpox vaccine supply during 2026 and 2027. The company also reported 2026 public-preparedness contracts totaling around DKK 2.2 billion at that time, showing how a small number of national orders can alter the regional revenue picture.
European suppliers also face a stricter need to manage product labels and post-authorization evidence across indications. Regulatory decisions can affect which threats a product may address even when national authorities retain it for other approved uses.
Asia-Pacific
Asia-Pacific accounted for an estimated 16.5% share, or USD 2.92 billion in 2025, and is expected to record the fastest regional expansion through 2035. China contributed 4.4% of global revenue, or USD 0.78 billion; Japan represented 3.6%, or USD 0.64 billion; and India held 2.2%, or USD 0.39 billion. Other Asia-Pacific markets generated USD 1.11 billion.
Japan’s opportunity is concentrated in national preparedness, vaccine capability and rapid diagnostics. China’s scale supports domestic manufacturing and surveillance investment, while India’s strengths in vaccines, active ingredients and contract production make it relevant to supply resilience. A January 2026 oral TPOXX order from an Asia-Pacific country, followed by 2026 delivery activity reported by SIGA, shows that international antiviral stockpiling is becoming a measurable commercial channel in the region.
Latin America
Latin America represented 3.9% of 2025 revenue, equal to USD 0.69 billion. Brazil and Mexico are the primary centers for public-health laboratories, vaccine infrastructure and emergency preparedness. Budget constraints encourage multilateral procurement and selective stockpiling. Suppliers with flexible pack sizes, long shelf life and training support are better positioned than vendors offering a product without an implementation plan.
Middle East and Africa
The Middle East and Africa accounted for 3.9%, or USD 0.69 billion in 2025. Gulf countries invest in strategic preparedness and advanced hospital systems, while African demand is closely connected to outbreak response, laboratory capacity and international partnerships. The region also provides operational evidence for countermeasures against viral hemorrhagic fevers. In June 2026, U.S. preparedness authorities reported support for an Ebola response using investigational medical countermeasures and technical assistance, reinforcing the role of response deployments in product validation and access planning.
Competitive Landscape
Emergent BioSolutions
Emergent has one of the broadest commercial medical-countermeasure portfolios. Its products cover anthrax, smallpox and mpox, botulism and Ebola. The 2025 portfolio included ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, CYFENDUS, EBANGA, raxibacumab and TEMBEXA. This range allows the company to participate in vaccine, antitoxin, antibody and antiviral procurement rather than relying on one modality.
The company reported USD 742.9 million in total 2025 revenue and more than USD 450 million in medical-countermeasure contract awards, option exercises and orders during the year. Named awards included USD 62.4 million for BAT, USD 56.0 million for ACAM2000, USD 51.9 million for CNJ-016 and USD 30.0 million for CYFENDUS. In September 2026, Emergent announced a CYFENDUS contract modification with a stated value of USD 24 million. Its strategic strength is portfolio depth; its operating exposure is the timing and concentration of government orders.
Bavarian Nordic
Bavarian Nordic’s biodefense position centers on the MVA-BN vaccine platform, marketed under regional brands including JYNNEOS, IMVANEX and IMVAMUNE. The non-replicating vaccine is used in smallpox and mpox preparedness and has become a significant product for national stockpiles.
In May 2026, the company announced U.S. government contract options covering production and supply of freeze-dried smallpox vaccine. In June, it reported a government contract worth more than DKK 700 million for deliveries during 2026 and 2027. At that point, 2026 public-preparedness contracts totaled around DKK 2.2 billion, and the company expected public-preparedness revenue of DKK 2.3-2.5 billion for the year. The freeze-dried presentation is strategically relevant because storage life and deployment logistics influence the total cost of maintaining a stockpile.
SIGA Technologies
SIGA specializes in tecovirimat, sold as oral and intravenous TPOXX. The product addresses orthopoxvirus preparedness and is procured by the United States and international governments. The availability of both oral and IV formulations gives health authorities options for patients who cannot take oral treatment or require hospital-based administration.
In 2025, SIGA recorded USD 53 million in oral TPOXX revenue and USD 26 million in IV TPOXX revenue from U.S. Strategic National Stockpile deliveries, plus USD 6 million from an international customer. In August 2026, the company reported USD 37 million in second-quarter product sales, including USD 24 million of IV TPOXX delivered to the U.S. stockpile and USD 13 million of oral TPOXX delivered to two international customers. SIGA’s focused model creates strong exposure to orthopox procurement, regulatory outcomes and the timing of a limited number of contracts.
DynPort Vaccine Company, a GDIT company
DynPort Vaccine Company provides development, licensure and program-management services for federal medical-countermeasure programs. Its capabilities include clinical research, process development, manufacturing oversight, regulatory affairs, quality assurance, analytical test development, nonclinical studies and complex program management.
The company reports experience with influenza, plague and botulinum vaccines, anti-infective products and treatments for nerve-agent exposure. It also supports FDA Animal Rule strategies and has moved six biodefense products into clinical development and one to licensure. DynPort’s role differs from a product manufacturer: it reduces execution risk between early technology and a government-ready countermeasure. That position becomes more valuable as agencies validate multiple rapid-response platforms in parallel.
Recent Developments
- October 16, 2026 - BARDA: The agency selected nine priority emerging viruses for rapid-response platform validation. The program tests whether technologies can reproduce development speed and quality across different viral families.
- September 1, 2026 - Emergent BioSolutions: The company announced a BARDA contract modification valued at USD 24 million for CYFENDUS anthrax vaccine supply.
- August 25, 2026 - BARDA: The agency expanded the SMART Antiviral Prize to USD 150 million and named nine concept-stage winners, creating a staged funding route for broad antiviral innovation.
- August 6, 2026 - SIGA Technologies: SIGA reported USD 37 million in second-quarter product sales, including USD 24 million in IV TPOXX deliveries to the U.S. stockpile and USD 13 million in oral TPOXX deliveries to international customers.
- June 26, 2026 - U.S. preparedness authorities: Federal authorities reported support for an Ebola response through investigational medical countermeasures and technical assistance, providing field evidence relevant to deployment planning.
- June 9, 2026 - Bavarian Nordic: The company received a government contract worth more than DKK 700 million for smallpox and mpox vaccine deliveries scheduled across 2026 and 2027.
- May 11, 2026 - Bavarian Nordic: The U.S. government exercised contract options for production and supply of freeze-dried smallpox vaccine, supporting longer-term stockpile logistics.
Strategic Key Takeaways
- The market adds USD 13.11 billion by 2035. Growth from USD 17.70 billion to USD 30.81 billion creates room for products and readiness services, but contract timing will keep company revenue uneven.
- Anthrax and smallpox/mpox jointly control 54.2% of 2025 revenue. Their combined USD 9.59 billion value makes established stockpile programs the primary commercial base through the early forecast period.
- Vaccines remain the largest countermeasure class at USD 6.99 billion. Differentiation is shifting toward dosing efficiency, storage profile, surge capacity and lifecycle economics.
- Rapid-response platforms are becoming procurement assets. BARDA’s nine-virus validation program creates a route for reusable technologies to win funding before a single pathogen produces routine demand.
- North America’s USD 9.35 billion position reflects a full procurement system. Research funding, advanced development, stockpiling and domestic manufacturing support are integrated, making execution capability as important as product novelty.
- Asia-Pacific is the fastest-expanding regional opportunity. International TPOXX orders provide evidence that countries outside North America and Europe are building targeted pharmaceutical stockpiles.
- Specialist development services have durable value. Animal Rule strategy, assay validation, quality systems and government program management remain bottlenecks that platform science alone does not solve.
